CERRI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.949
EU - Europa 12.025
AS - Asia 8.618
SA - Sud America 1.305
AF - Africa 188
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 13
Totale 39.125
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.660
IT - Italia 5.727
SG - Singapore 2.932
GB - Regno Unito 2.380
CN - Cina 2.124
HK - Hong Kong 1.003
BR - Brasile 987
VN - Vietnam 967
SE - Svezia 773
DE - Germania 684
FR - Francia 506
FI - Finlandia 380
RU - Federazione Russa 371
UA - Ucraina 306
KR - Corea 248
TR - Turchia 245
NL - Olanda 230
IN - India 225
ID - Indonesia 191
BG - Bulgaria 130
JP - Giappone 130
CA - Canada 123
MX - Messico 123
AR - Argentina 103
BD - Bangladesh 102
IE - Irlanda 92
IQ - Iraq 75
PL - Polonia 63
ES - Italia 61
PK - Pakistan 61
ZA - Sudafrica 56
EC - Ecuador 49
BE - Belgio 47
CO - Colombia 39
AT - Austria 35
RO - Romania 34
VE - Venezuela 34
AE - Emirati Arabi Uniti 33
LT - Lituania 32
CL - Cile 30
MA - Marocco 28
CH - Svizzera 26
MY - Malesia 26
SA - Arabia Saudita 26
TW - Taiwan 24
EG - Egitto 23
JO - Giordania 23
PE - Perù 22
TN - Tunisia 20
AU - Australia 18
DZ - Algeria 18
IR - Iran 18
PY - Paraguay 18
UZ - Uzbekistan 18
AZ - Azerbaigian 16
CZ - Repubblica Ceca 16
KE - Kenya 16
TH - Thailandia 16
NP - Nepal 15
PH - Filippine 14
UY - Uruguay 14
AL - Albania 13
LV - Lettonia 13
DK - Danimarca 12
DO - Repubblica Dominicana 12
HR - Croazia 11
IL - Israele 11
HU - Ungheria 10
RS - Serbia 10
NZ - Nuova Zelanda 9
EU - Europa 8
GE - Georgia 8
SN - Senegal 8
BO - Bolivia 7
EE - Estonia 7
KG - Kirghizistan 7
NO - Norvegia 7
SI - Slovenia 7
SY - Repubblica araba siriana 7
GR - Grecia 6
KZ - Kazakistan 6
OM - Oman 6
PT - Portogallo 6
BH - Bahrain 5
BY - Bielorussia 5
ET - Etiopia 5
JM - Giamaica 5
LB - Libano 5
PS - Palestinian Territory 5
CY - Cipro 4
KH - Cambogia 4
KW - Kuwait 4
LU - Lussemburgo 4
MD - Moldavia 4
MK - Macedonia 4
QA - Qatar 4
BZ - Belize 3
CR - Costa Rica 3
HN - Honduras 3
LI - Liechtenstein 3
Totale 39.067
Salva come PNG Salva come JPEG
Città #
Singapore 1.983
Ashburn 1.765
Fairfield 1.687
Santa Clara 1.680
Southend 1.635
Woodbridge 987
Hong Kong 976
Chandler 947
Houston 749
San Jose 645
Seattle 613
Wilmington 546
Cambridge 515
Hefei 514
Beijing 475
Dearborn 469
Ann Arbor 444
Nyköping 444
Jacksonville 424
Milan 411
London 367
Rome 359
Council Bluffs 300
Ho Chi Minh City 268
Helsinki 261
The Dalles 259
New York 249
Hanoi 242
Modena 231
Los Angeles 210
Seoul 204
San Diego 176
Chicago 170
Jakarta 145
Naples 129
Bologna 124
Sofia 124
Princeton 123
Lauterbourg 117
Dallas 110
Florence 109
Eugene 105
Tokyo 102
Shanghai 96
Palermo 95
Munich 94
Izmir 93
Moscow 93
São Paulo 85
Redwood City 83
Orem 82
Buffalo 81
Salt Lake City 79
Bari 75
Dublin 67
Frankfurt am Main 65
Catania 64
Phoenix 59
Turin 58
Bremen 56
Columbus 54
Reggio Emilia 53
Boardman 52
Da Nang 46
Mexico City 45
Montreal 43
Genoa 40
Guangzhou 40
San Francisco 39
Warsaw 39
Brussels 38
Chennai 38
Verona 38
Atlanta 37
Dong Ket 36
Elk Grove Village 35
Padova 35
Haiphong 34
Brooklyn 33
Nuremberg 33
Parma 32
Poplar 32
Rio de Janeiro 32
Cagliari 31
Denver 30
Tampa 30
Turku 29
Baghdad 28
Redondo Beach 28
Lahore 27
Manchester 27
Ankara 26
Falls Church 26
Mountain View 26
Norwalk 26
Boston 25
Toronto 25
Mumbai 24
Stockholm 23
Amman 22
Totale 25.075
Salva come PNG Salva come JPEG
Nome #
INTERSTIZIOPATIA POLMONARE NON CLASSIFICABILE O SECONDARIA A CONNETTIVITE INDIFFERENZIATA. IMPORTANZA E DIFFICOLTÀ DI UNA DIAGNOSI DIFFERENZIALE. 3.815
Malattie infiltrative diffuse del polmone 1.152
Multidrug-resistant tuberculosis outbreak in an Italian prison: Tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays 784
Non-steroid agents for idiopathic pulmonary fibrosis 454
Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis 405
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 399
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 394
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 392
Acute exacerbation of Idiopathic Pulmonary Fibrosis: lessons learned from the Acute Respiratory Distress Syndrome 371
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 356
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. 350
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments 349
Effectiveness of pulmonary rehabilitation in patients with INTERSTITIAL LUNG DISEASE of different etiology: a multicenter prospective study 345
Proteomics Analysis of Formalin-Fixed Paraffine-Embedded Tissue Reveals Key Proteins Related to Lung Dysfunction in Idiopathic Pulmonary Fibrosis. 344
Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease 338
Radiologic classification of usual interstitial pneumonia in rheumatoid arthritis-related interstitial lung disease: correlations with clinical, serological and demographic features of disease 336
NEW PERSPECTIVES IN DIAGNOSIS OF INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS. VALIDATION STUDY OF AN ELECTRONIC STETHOSCOPE AND AD HOC SOFTWARE FOR DETECTION OF PULMONARY CRACKLES 329
INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS. WHAT DO WE DON’T KNOW? THE LIRA STUDY (LUNG INVOLVEMENT IN RHEUMATOID ARTHRITIS) 320
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 317
Use of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Case Study 315
Comparison of the tubercolin skin test and the ellispot blood test for the diagnosis of latent tuberculosis infection in pre-transplant dialysis patients 313
Role Of The QFT-IT Assay For The Diagnosis Of Latent Tuberculosis Infection Among Adult Immigrants 312
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review 300
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 298
Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement 297
Emerging drugs for idiopathic pulmonary fibrosis. 296
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis. 295
Rifabutin for treating pulmonary tuberculosis. 294
Home Oxygen Saturation Monitoring And Quality Of Life Evaluation In Patients With Idiopathic Pulmonary Fibrosis: Preliminary Results From A Prospective Multicenter Trial 294
Best supportive care for idiopathic pulmonary fibrosis: Current gaps and future directions 293
Lung fibrosis, bone marrow fibrosis and liver cirrhosis: A Short Telomere Syndrome or a casual association? 292
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. 291
Management of idiopathic pulmonary fibrosis. 290
Molecular mechanisms and cellular contribution from lung fibrosis to lung cancer development. 290
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 289
A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM) 286
Morbidity and Mortality in Patients with Idiopathic Pulmonary Fibrosis Undergoing Diagnostic Surgical Lung Biopsy 286
Clinical differences in sarcoidosis patients with and without lymphoma: a single-center retrospective cohort analysis. 286
Pulmonary fibrosis and the many faces of UIP 284
Serial Ultrasound Assessment of Diaphragmatic Function and Clinical Outcome in Patients with Amyotrophic Lateral Sclerosis. 281
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy 280
Prevalence Of Subclinical Liver Fibrosis Among Patients With Idiopathic Pulmonary Fibrosis 280
Pulmonary stretch and lung mechanotransduction: Implications for progression in the fibrotic lung 280
Expression of HOXB7 in the lung of patients with idiopathic pulmonary fibrosis: a proof of concept study. 279
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 278
Fibrotic idiopathic interstitial lung disease: the molecular and cellular key players. 278
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis 277
HRCT Patterns Of Usual Interstitial Pneumonia In Rheumatoid Lung 277
Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature 276
AB1157 VALIDATION OF VECTOR (VELCRO CRACKLES DETECTOR) FOR THE DIAGNOSIS OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH CONNECTIVE TISSUE DISEASES 276
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report 274
Interstitial pneumonia with autoimmune features: A single center prospective follow-up study 268
Quantiferon-TB Gold In-Tube Tests In Hospital Health Care Workers: A Five Years Experience 267
Management of Idiopathic Pulmonary Fibrosis 267
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis 267
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 264
Inspiratory effort and respiratory mechanics in spontaneously breathing patients with acute exacerbation of idiopathic pulmonary fibrosis: a retrospective matched control study. 261
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 260
Ultrasound assessed Diaphragm Impairment is a Predictor of Outcomes in Acute Exacerbation of Chronic Obstructive Pulmonary Disease undergoing Non-Invasive Ventilation. 259
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust 258
Sarcoidosis: challenging diagnostic aspects of an old disease. 256
The encaged lung: rapidly progressive idiopathic pleurisy. 255
Smoking-related interstitial lung disease 251
UNCLASSIFIABLE INTERSTITIAL LUNG DISEASE OR UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE? A CHALLENGING DIFFERENTIAL DIAGNOSIS 250
Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study 250
Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay 247
Real-life comparison of Pirfenidone and Nintedanib in patients with Idiopathic Pulmonary Fibrosis: a 24-month assessment. 245
Pulmonary Carcinosarcoma Arising in the Framework of an Idiopathic Pulmonary Fibrosis 244
INTERSTITIAL LUNG DISEASE IS ASSOCIATED TO INFECTIONS OF LOWER RESPIRATORY TRACT IN IMMUNOCOMPROMISED RHEUMATOID ARTHRITIS PATIENTS 242
AB0472 PRIMARY SJOGREN SYNDROME ASSOCIATED INTERSTITIAL LUNG DISEASE: FEATURES, TREATMENT AND OUTCOME OF A MONOCENTRIC COHORT 240
The big clinical trials in idiopathic pulmonary fibrosis. 237
RHEUMATOID ARTHRITIS RELATED INTERSTITIAL LUNG DISEASE. RADIOLOGICAL PATTERNS AND CORRELATIONS WITH CLINICAL, SEROLOGICAL AND DEMOGRAPHIC FEATURES OF DISEASE 236
Validation of a Method for Automatic Detection of Lung Sounds in Fibrotic Interstitial Lung Disease 234
Genetic commonality between inflammatory bowel disease and sarcoidosis: the beginning of the end or the end of the beginning? 233
Identification Of Potential Candidate Biomarkers In Lymphangioleiomyomatosis Using ITRAQ Proteomic Technology 233
Empoyment of the ELISPOT blood test for the diagnosis of latent tuberculosis infection in dialysis patients awaiting renal transplantation 231
Inappropriatezza prescrittiva dell'ossigenoterapia domiciliare a lungo termine 230
Biological effects of COVID-19 on lung cancer: can we drive our decisions? 228
Challenges in idiopathic interstitial lung disease 228
Interstitial lung disease is associated to infections of lower respiratory tract in immunocompromised rheumatoid arthritis patients 226
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis 226
The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease 226
Janus-faced amiodarone-induced pneumopathy 226
Repeated Quantiferon-TB Gold In-Tube Tests In Routine Clinical Practice: A Five Years Experience 224
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 221
Tubercolosi 219
Etiology and Level of Lung Derangement Do Not Affect the Beneficial Effect of Pulmonary Rehabilitation in Patients with Interstitial Lung Diseases 219
Erratum: Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature (Journal of Thoracic Disease (2019) 11 (1621-1628) DOI: 10.21037/jtd.2019.03.28) 217
Levels Of Fibulin-1 In The Lung And Serum Are Increased In Fibrotic Interstitial Lung Disease 215
Dissecting the role of mesenchymal stem cells in idiopathic pulmonary fibrosis: cause or solution? 212
Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review 209
Human mucosal associated invariant T cells detect bacterially infected cells 205
Unusual effectiveness of systemic steroids in Whipple disease. 203
Impact of Mesenchymal Stromal/stem Cell Infusions on Circulating Inflammatory Biomarkers in COVID-19 Patients: Analysis of a Phase I-IIa Trial. 201
Genetic testing in diffuse parenchymal lung disease 201
CHARACTERIZATION OF ANTI-MPO POSITIVE INTERSTITIAL LUNG DISEASE. CLINICAL-SEROLOGIC AND RADIOLOGIC FEATURES AND SURVIVAL 200
FRI0613 THERAPEUTIC STRATEGIES AND SURVIVAL IN PATIENTS WITH INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES 200
Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases. 200
Physiological effects of lung protective ventilation in patients with lung fibrosis and usual interstitial pneumonia pattern versus primary ARDS: a matched-control study. 195
Copd, pulmonary fibrosis and ilas in aging smokers: The paradox of striking different responses to the major risk factors 194
Totale 32.167
Salva come PNG Salva come JPEG
Categoria #
all - tutte 131.977
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 131.977
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021893 0 0 0 0 0 0 0 0 0 404 264 225
2021/20222.947 229 293 156 210 142 187 146 156 332 226 495 375
2022/20233.613 349 340 237 313 360 424 166 381 428 144 260 211
2023/20243.644 172 201 235 342 471 373 470 407 127 145 305 396
2024/20257.344 315 177 220 503 1.353 982 670 458 755 337 667 907
2025/202611.205 870 496 975 1.429 1.881 905 1.649 717 1.299 984 0 0
Totale 39.476